Company intelligence / Profile preview
Bloom Science
San Diego, California, United Statesbloomscience.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Bloom Science has reported positive data from a Phase 1 trial of its lead candidate BL‑001, demonstrating statistically significant, durable weight loss in overweight individuals. BL‑001 is designed to replicate the therapeutic effects of the ketogenic diet. The company plans to initiate Phase 2 studies in both obesity and Dravet syndrome. Preclinical data also support efficacy in seizure prevention.
- Therapeutic areas
- NeurologyMetabolic Disorders
- Modalities
- Live Biotherapeutic Products (LBPs)Orally delivered pharmaceutical therapies based on commensal microbesSynthetic biology-derived therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Leaps by Bayer (lead investor)ALS Investment FundApollo Health VenturesJoyance Partners
Beyond the preview
Go deeper on Bloom Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bloom Science.